| Patient | Liliʻuokalani |
|---|---|
| Date of birth | 1838-09-02 |
| Identifiers | MRN HR-ET024-SYN-TD; SSN (made up) 000-24-3086 |
| Document date | 1917-06-15 |
| Author | Kealani Morrison-Takeda, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month review after the stroke. [S]
Liliʻuokalani returns three months after the stroke. She has had no new neurological symptoms. The nosebleed four weeks ago has not recurred since she began using a nasal gel and a humidifier. She takes apixaban twice daily and has missed no doses. She plays the piano and has resumed composing, though she tires at the end of a long day. Her home blood pressure averages 124/72. She had a video review with Dr. Abernethy-Sato last week, who agreed with apixaban and the current plan. She has had no falls. She sleeps well and does not snore, by her household's account. [S]
| Element | Detail |
|---|---|
| Function | Composing and playing daily; modified Rankin Scale 1 |
| Mood | PHQ-9 4 |
| Home blood pressure | Average 124/72 mmHg |
| Anticoagulant | No missed doses; one minor nosebleed four weeks ago |
| Sleep | STOP-Bang 2 (age and treated blood pressure) |
| System | Result | Finding |
|---|---|---|
| Neurological | Negative | No weakness, numbness, speech, vision or balance problem |
| Hematologic | Negative | No further nosebleeds; no black stools or blood in the urine |
| Psychiatric | Negative | Mood steady; sleeping well |
| Constitutional | Positive | Tired at the end of long days |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release oral tablet, one tablet daily for 21 days, after a 325 mg loading dose in the emergency department | One tablet daily for 21 days | Oral route | 1917-03-16 to 1917-04-06 | completed | S |
| Clopidogrel 75 mg oral tablet, one tablet daily, after a 300 mg loading dose in the emergency department | One tablet daily | Oral route | 1917-03-16 to 1917-04-20 | completed | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1917-03-16 | active | S |
| Losartan 25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1917-03-23 | active | S |
| Apixaban 5 mg oral tablet, one tablet twice daily | One tablet twice daily | Oral route | 1917-04-20 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1917-06-15 | Body height | 160 | cm | S |
| 1917-06-15 | Body weight | 57.6 | kg | S |
| 1917-06-15 | Body mass index (BMI) [Ratio] | 22.5 | kg/m2 | S |
| 1917-06-15 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1917-06-15 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1917-06-15 | Heart rate | 70 | /min | S |
| 1917-06-15 | Respiratory rate | 16 | /min | S |
| 1917-06-15 | Body temperature | 36.6 | Cel | S |
| 1917-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1917-06-15 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1917-06-15 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1917-06-15 | Creatinine [Mass/volume] in Serum or Plasma | 0.84 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1917-06-15 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1912)/1.73 sq M | 71 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1917-06-15 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 70-99 mg/dL | Normal | S |
| 1917-06-15 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 11.6-15 g/dL | Normal | S |
| 1917-06-15 | Modified rankin scale | 1 | {score} | S | ||
| 1917-06-15 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S |
Vital signs recorded on 1917-06-15; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 126/74, pulse 70 and regular; weight 57.6 kg |
| Neurological | Normal speech, strength, fine finger movements and gait |
| Nose | Left anterior septum healed; no crusting |
| Musculoskeletal | Timed Up and Go 11 seconds |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Transient weakness and clumsiness of the right hand with word-finding difficulty, lasting about 20 minutes and fully resolved, the afternoon before the visit; suspected transient ischemic attack, ABCD2 score 5 (high risk); NIH Stroke Scale 0 | resolved | provisional | G45.9 | S — Synthetic presenting problem; resolved into the stroke diagnosis when diffusion MRI showed a small infarct at the stroke clinic the next day. Not a claim about her real symptoms. |
| Minor ischemic stroke: a small acute infarct in the cortex of the left precentral gyrus (left middle cerebral artery territory) on diffusion MRI, embolic in pattern, with full recovery (NIH Stroke Scale 0); source found to be paroxysmal atrial fibrillation; synthetic modern episode linked to her documented death from a stroke | active | confirmed | I63.412 | S — Synthetic modern diagnosis made at the stroke clinic the day after the visit; the 1917 cause of death remains D. |
| Hypertension: told of borderline readings in past years and not treated; 156/88 mmHg at intake | active | confirmed | I10 | S — Synthetic risk factor; no blood pressure from her lifetime is recorded in the cited sources. |
| Paroxysmal atrial fibrillation found on 30-day ambulatory monitoring after the stroke (six episodes, the longest 3 hours 10 minutes; burden about 3%); CHA2DS2-VASc 6, HAS-BLED 2 | active | confirmed | I48.0 | S — Synthetic finding on prolonged rhythm monitoring at five weeks. |
| Anterior nosebleed from the left side of the nasal septum four weeks after starting apixaban, stopped with pressure; hemoglobin unchanged; resolved | resolved | confirmed | R04.0 | S — Synthetic intercurrent problem at an unscheduled visit; a common minor bleed on an anticoagulant, not a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure in the clinic and at home (target below 130/80 mmHg) and weight | Every visit | Completed today | 126/74 mmHg; home average 124/72; 57.6 kg |
| Laboratory | Potassium and creatinine after starting an angiotensin receptor blocker | About two weeks after starting, then every six months | Completed today | Potassium 4.4 mmol/L, creatinine 0.84 mg/dL (eGFR 71) |
| Medication safety | Antithrombotic therapy and adherence | Every visit | Completed today | Apixaban twice daily, no missed doses; one minor nosebleed, managed without stopping it |
| Laboratory | Anticoagulant safety: blood count, kidney function (creatinine clearance) and liver tests | Before starting, then about every creatinine clearance / 10 months at age 75 or older (about every five months for her) | Completed today | Hemoglobin 12.6 g/dL; creatinine 0.84 mg/dL |
| Survey | Neurological status (NIH Stroke Scale at the event; modified Rankin Scale at 90 days) and new symptoms | Modified Rankin Scale at 90 days | Completed today | Modified Rankin Scale 1; no new symptoms |
| Survey | Depression screen (PHQ-2, PHQ-9) | At the first post-stroke visit, then at least yearly | Completed today | PHQ-9 4; item 9 scored 0 |
| Survey | Cognitive screen (MoCA) | After the event, again within the first year, then periodically | Up to date | MoCA 26 after the stroke; repeat at the five-month review |
| Laboratory | Lipid panel (LDL goal below 70 mg/dL) | Four to twelve weeks after starting a statin, then every three to twelve months | Up to date | LDL 64 mg/dL at five weeks; repeat at five months |
| Examination | Falls risk | Every visit | Completed today | No falls; Timed Up and Go 11 seconds |
| Survey | Obstructive sleep apnea screen (STOP-Bang) | After a stroke | Completed today | STOP-Bang 2: low risk; no sleep study needed |
| Referral | Rehabilitation (physical, occupational and speech therapy) | At discharge and during recovery | Not indicated | No residual deficit; modified Rankin Scale 1 |
| Self-management | Tobacco, alcohol and physical activity | Every visit | Completed today | Never smoker; alcohol rarely; walks daily |
| Self-management | BE FAST and calling 911 | Every visit | Completed today | Reviewed |
| Self-management | Culturally safe care: her choices, ʻohana involvement and Native Hawaiian healing alongside clinic care | Every visit | Completed today | Lomilomi continues by her choice; her ʻohana is involved as she wishes |
Goal progress:
Guideline basis: 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association (2021); Primary Care of Adult Patients After Stroke: A Scientific Statement From the American Heart Association/American Stroke Association (2021); 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, stroke and transient ischemic attack, atrial fibrillation and hypertension monographs (2026); Signs and Symptoms of Stroke (2026); Ke Ola Mamo: a Native Hawaiian Health Care System serving Oʻahu (medical care, lomilomi and community health workers) (2026); Falls Prevention in Community-Dwelling Older Adults: Interventions (2024)
Follow-up: Annual wellness visit in four weeks. Five-month review in ten weeks with a lipid panel, blood count, kidney function and the MoCA. Call 911 for any BE FAST sign. Next scheduled visit 1917-07-13: subsequent annual wellness visit. [S]